FDA Approves Medtronic’s Resolute Onyx DES With Short-Term Dual-Antiplatelet Therapy

The agency approved Medtronic's zotarolimus-eluting coronary stent for patients with a high bleeding risk who are treated with one month of dual-antiplatelet therapy.

MDT Onyx Clear
Medtronic's Resolute Onyx zotarolimus-eluting coronary stent • Source: Medtronic PLC

The US Food and Drug Administration expanded the approved indication for Medtronic plc’s Resolute Onyx zotarolimus-eluting coronary stent to include patients at high risk for bleeding who will be on dual-antiplatelet therapy for just one month following the intervention.

Resolute Onyx is the only drug-eluting stent approved by the FDA for patients who can only tolerate a one-month regimen...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Approvals

More from Policy & Regulation